NCT06054932View on ClinicalTrials.gov

Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 5, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

March 30, 2026

Conditions
Advanced Solid Tumor
Interventions
DRUG

LK101 injection

LK101 administrated Q2W as the prime dose, and Q3W in the boost phase

DRUG

LK101 injection

LK101 administrated QW as the prime dose, and Q3W in the boost phase

Trial Locations (2)

100021

RECRUITING

Beijing Cancer Hospital, Beijing

NOT_YET_RECRUITING

Cancer hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Beijing Likang Life Science and Tech Co., Ltd.

INDUSTRY